Therapeutic drug monitoring of osimertinib in EGFR mutant non-small cell lung cancer by dried blood spot and plasma collection: A pilot study.
Sathya NarayananAlexander YuileBharat VenkateshMatthew McKayMalinda ItchinsNick PavlakisHelen WheelerLauren GrayJoe WeiSamuel MillerBrendan KirwinMark P MolloyStephen ClarkePublished in: British journal of clinical pharmacology (2024)
As such, we demonstrate that TDM for osimertinib is practical for future trials. We also validated the use of DBS as an alternative to conventional quantitation for exploration of TDM for osimertinib in larger trials and for other targeted therapies.